Bolt Biotherapeutics Appoints Dr. Nils Lonberg to its Scientific Advisory Board
REDWOOD CITY, Calif., Feb. 20, 2020 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced the addition of Nils Lonberg, Ph.D., to its scientific advisory board (SAB). Dr. Lonberg, current executive-in-residence at Canaan Partners, has over 30 years of experience in the biopharmaceutical industry, contributing extensively to drug discovery and development in cancer immunotherapy.
"Dr. Lonberg's team developed a transgenic platform that led to multiple FDA-approved antibody products and he led the drug discovery efforts for checkpoint inhibitor antibody therapies ipilimumab and nivolumab. This proven expertise in immuno-oncology drug discovery and development will be highly beneficial as we strengthen and expand our pipeline of innovative immunotherapies," stated David Dornan, Ph.D., Bolt's senior vice president of research. "Additionally, as we initiate our first clinical study this quarter and build our pipeline of innovative Boltbody™ investigational products, we are grateful to have Dr. Lonberg's extensive immuno-oncology knowledge and shared commitment to developing new treatments for cancer patients unresponsive to checkpoint inhibitors."
Dr. Lonberg added, "The Boltbody™ platform is extremely promising, especially given the preclinical results that demonstrate complete regression of trastuzumab refractory tumors and immunological memory that even targets the parental tumor that lost HER2 expression. Bolt's technology platform has the potential to apply to a broad range of cancers. I look forward to assisting Bolt in harnessing this technology to bring therapeutic candidates to patients who have limited treatment options."
Dr. Lonberg is an executive-in-residence at Canaan Partners, an early-stage venture capital firm. Prior to Canaan, Dr. Lonberg spent 10 years with Bristol-Myers Squibb leading drug discovery efforts for immuno-oncology, most recently serving as the senior vice president for Oncology Discovery Biology. Before working at Bristol-Myers Squibb, Dr. Lonberg was the scientific director at Medarex and GenPharm, leading drug discovery and focusing on antibody-targeting and immune-modulating therapies for cancer treatment. Under his leadership, YERVOY® (ipilimumab) was the first-ever checkpoint blockade therapy to gain regulatory approval in 2011, and the second, OPDIVO® (nibolumab), was approved in 2014. Dr. Lonberg completed his postdoctoral fellowship at Memorial Sloan Kettering Cancer and received his Ph.D. in Biochemistry and Molecular Biology from Harvard University. He was elected to the National Academy of Engineering in 2015.
About Bolt Biotherapeutics' Immune-Stimulating Antibody Conjugate (ISAC) Platform Technology
About Bolt Biotherapeutics, Inc.
Investor Relations Contact:
View original content to download multimedia:http://www.prnewswire.com/news-releases/bolt-biotherapeutics-appoints-dr-nils-lonberg-to-its-scientific-advisory-board-301007909.html
SOURCE Bolt Biotherapeutics, Inc.